Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study highlights risks of subcutaneous ureteral bypass placement
Major complications from SUB occurred in 48 per cent of the cats studied.

Researchers analyse the medical records of 95 cats fitted with SUB devices.

Subcutaneous ureteral bypass (SUB) placement is associated with a high complication rate, according to new research.

The study, published in the Journal of Small Animal Practice (JSAP), found that most of these complications are manageable, resulting in an average survival time of over two years. It also suggests that imaging techniques, such as fluoroscopy, are useful in identifying complications. 

In the study, researchers analysed the medical record of  95 cats fitted with SUBs between April 2012 and June 2017. The information recorded included imaging modality used for diagnosis, whether urethral catheterisation was performed and whether obstruction was uni- or bilateral. 

They found that minor complications - defined as infection or technical problem which resolved with none or minor treatment - occurred in 19 per cent of the cats. Major complications - defined as infection or technical problem resulting in revision surgery, removal of the SUBs or death/euthanasia – occurred in 48 per cent of the cats. Eleven per cent of cats analysed in the study did not survive to discharge. 

Dr Nicola Kulendra, lead author for the paper said: “A significant association between long-term survival and creatinine at presentation was identified. The median survival time for cats presenting with creatinine concentration ≥440 μmol/L (International Renal Interest Society stage acute kidney injury (AKI) 4 and 5) was 530 days, compared to a median survival time of 949 days for those cats presenting with creatinine <440 μmol/L (International Renal Interest Society stage AKI 1–3).”

JSAP editor Nicola Di Girolamo, concluded: “Veterinary medicine is advancing fast and it is exciting to see treatment options that just a decade ago were rarely considered are now accessible to many of our patients. Furthermore, it is excellent to see the veterinary sector is publishing articles of this nature, demonstrating the risks and complications of a procedure, to support proper discussion with owners and referring veterinarians.”

Image © BSAVA Manual of Canine and Feline Abdominal Surgery 2nd Ed.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.